SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+1.07%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.36B
AUM Growth
+$1.36B
(+13%)
Cap. Flow
+$221M
Cap. Flow
% of AUM
16.22%
Top 10 Holdings %
Top 10 Hldgs %
57.49%
Holding
75
New
17
Increased
12
Reduced
20
Closed
14
Top Buys
| 1 |
Gilead Sciences
GILD
|
$71.5M |
| 2 |
AbbVie
ABBV
|
$63.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
$52.1M |
| 4 |
Stryker
SYK
|
$41.8M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
$38.9M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$86.5M |
| 2 |
Elanco Animal Health
ELAN
|
$51.7M |
| 3 |
IDEAYA Biosciences
IDYA
|
$17.5M |
| 4 |
Incyte
INCY
|
$13.1M |
| 5 |
Edwards Lifesciences
EW
|
$12.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $245M | 17.88% | 1,550,280 | – | – |
|
2
Vera Therapeutics
VERA
$1.38B
| $118M | 8.61% | 2,793,987 | – | – |
|
|
3
Gilead Sciences
GILD
$140B
| $71.5M | 5.21% | +774,227 | New | +$71.5M |
|
|
4
AbbVie
ABBV
$372B
| $63.9M | 4.65% | +359,393 | New | +$63.9M |
|
|
5
Jazz Pharmaceuticals
JAZZ
$7.75B
| $62.1M | 4.52% | 504,193 +315,631 | +167% | +$38.9M |
|
|
6
Sarepta Therapeutics
SRPT
$1.78B
| $52.1M | 3.8% | +428,771 | New | +$52.1M |
|
7
ArriVent BioPharma
AVBP
$776M
| $45.2M | 3.29% | 1,696,752 | – | – |
|
8
AstraZeneca
AZN
$248B
| $42.7M | 3.11% | 651,344 -158,062 | -20% | -$10.4M |
|
|
9
Stryker
SYK
$150B
| $41.8M | 3.04% | +116,005 | New | +$41.8M |
|
10
Axsome Therapeutics
AXSM
$6.05B
| $41.6M | 3.03% | 491,726 +112,199 | +30% | +$9.49M |
|
11
Replimune Group
REPL
$422M
| $38.1M | 2.78% | 3,149,522 +3,101,384 | +6,443% | +$37.6M |
|
|
12
Incyte
INCY
$16.5B
| $36.2M | 2.64% | 524,267 -189,909 | -27% | -$13.1M |
|
|
RAPP
13
Rapport Therapeutics
RAPP
$643M
| $35.4M | 2.58% | 1,995,594 | – | – |
|
14
Soleno Therapeutics
SLNO
$3.6B
| $34M | 2.48% | 757,248 +170,904 | +29% | +$7.68M |
|
15
Boston Scientific
BSX
$156B
| $31M | 2.25% | 346,571 +210,752 | +155% | +$18.8M |
|
|
16
IDEAYA Biosciences
IDYA
$2.15B
| $27.5M | 2% | 1,069,090 -680,365 | -39% | -$17.5M |
|
17
Alnylam Pharmaceuticals
ALNY
$58.5B
| $25.9M | 1.89% | +110,157 | New | +$25.9M |
|
18
Alkermes
ALKS
$4.78B
| $25.7M | 1.87% | +894,266 | New | +$25.7M |
|
19
Dyne Therapeutics
DYN
$1.92B
| $25.2M | 1.84% | 1,071,498 +299,428 | +39% | +$7.05M |
|
20
DexCom
DXCM
$29.5B
| $22.6M | 1.64% | +290,210 | New | +$22.6M |
|
21
Rhythm Pharmaceuticals
RYTM
$6.85B
| $22.2M | 1.62% | 397,428 +120,750 | +44% | +$6.76M |
|
22
Globus Medical
GMED
$8.27B
| $20.2M | 1.47% | +244,700 | New | +$20.2M |
|
23
Intuitive Surgical
ISRG
$170B
| $19.8M | 1.44% | +37,896 | New | +$19.8M |
|
24
Insmed
INSM
$28.8B
| $17.7M | 1.29% | 256,281 -30,026 | -10% | -$2.07M |
|
25
Y-mAbs Therapeutics
YMAB
$388M
| $17.2M | 1.25% | 2,194,278 | – | – |
|